The 4-drug combination of rituximab (Rituxan), bendamustine, bortezomib (Velcade), and dexamethasone (RiBVD) was found to improve progression-free survival (PFS) and demonstrated a tolerable safety profile as frontline treatment for patients with mantle cell lymphoma (MCL) who are ≥65 years, according to results of a multicenter, prospective, phase II trial.
Moreover, the 2- and 4-year overall survival (OS) rates were 81.1% and 71.3%, respectively.
“…Our results identify the combination of rituximab, bendamustine, bortezomib, and dexamethasone, without maintenance therapy, as a promising treatment option in MCL patients ≥65 years old," said investigators of the study, which was led by Remy Gressin, MD, of the Center Hospital University of Grenoble, France. "The RiBVD regimen compares favorably with other treatment strategies used in this setting, although randomized trials are still lacking.”
... to read the full story